Zacks Research Issues Negative Estimate for ACHC Earnings

Acadia Healthcare Company, Inc. (NASDAQ:ACHC) – Zacks Research decreased their Q2 2026 earnings estimates for shares of Acadia Healthcare in a research note issued to investors on Wednesday, March 11th. Zacks Research analyst Team now forecasts that the company will post earnings of $0.49 per share for the quarter, down from their prior forecast of $0.66. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Acadia Healthcare’s current full-year earnings is $3.38 per share. Zacks Research also issued estimates for Acadia Healthcare’s FY2026 earnings at $1.48 EPS and FY2027 earnings at $1.55 EPS.

Acadia Healthcare (NASDAQ:ACHC) last announced its quarterly earnings results on Wednesday, February 25th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.04. The firm had revenue of $821.46 million during the quarter, compared to the consensus estimate of $800.10 million. Acadia Healthcare had a negative net margin of 33.29% and a positive return on equity of 6.53%. The firm’s revenue for the quarter was up 6.1% compared to the same quarter last year. During the same quarter last year, the firm earned $0.64 EPS. Acadia Healthcare has set its FY 2026 guidance at 1.300-1.550 EPS and its Q1 2026 guidance at 0.250-0.300 EPS.

A number of other equities analysts have also recently commented on ACHC. KeyCorp dropped their target price on Acadia Healthcare from $30.00 to $25.00 and set an “overweight” rating for the company in a report on Wednesday, December 3rd. Deutsche Bank Aktiengesellschaft lowered their price target on Acadia Healthcare from $33.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, December 3rd. Weiss Ratings reiterated a “sell (d)” rating on shares of Acadia Healthcare in a research report on Wednesday, January 21st. Royal Bank Of Canada increased their target price on shares of Acadia Healthcare from $17.00 to $28.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Finally, Mizuho lowered their target price on shares of Acadia Healthcare from $22.00 to $17.00 and set a “neutral” rating for the company in a report on Thursday, December 18th. Seven equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Acadia Healthcare has an average rating of “Hold” and an average target price of $21.15.

Acadia Healthcare Trading Down 2.6%

Shares of ACHC stock opened at $23.52 on Friday. The company has a market cap of $2.17 billion, a PE ratio of -1.93, a price-to-earnings-growth ratio of 8.16 and a beta of 0.74. Acadia Healthcare has a 1 year low of $11.43 and a 1 year high of $31.04. The stock’s 50 day simple moving average is $16.80 and its two-hundred day simple moving average is $18.78. The company has a debt-to-equity ratio of 1.27, a current ratio of 1.55 and a quick ratio of 1.55.

Institutional Trading of Acadia Healthcare

Several institutional investors and hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP boosted its stake in shares of Acadia Healthcare by 24.9% during the fourth quarter. Wellington Management Group LLP now owns 11,774,308 shares of the company’s stock valued at $167,077,000 after purchasing an additional 2,350,760 shares during the period. Vanguard Group Inc. increased its stake in Acadia Healthcare by 7.8% in the 3rd quarter. Vanguard Group Inc. now owns 9,417,045 shares of the company’s stock worth $233,166,000 after buying an additional 681,278 shares during the period. Goldman Sachs Group Inc. lifted its holdings in Acadia Healthcare by 417.8% during the 4th quarter. Goldman Sachs Group Inc. now owns 4,728,613 shares of the company’s stock valued at $67,099,000 after buying an additional 3,815,471 shares in the last quarter. Abrams Bison Investments LLC lifted its holdings in Acadia Healthcare by 22.3% during the 3rd quarter. Abrams Bison Investments LLC now owns 4,380,000 shares of the company’s stock valued at $108,449,000 after buying an additional 800,000 shares in the last quarter. Finally, UBS Group AG boosted its position in Acadia Healthcare by 8.8% in the 3rd quarter. UBS Group AG now owns 4,336,698 shares of the company’s stock valued at $107,377,000 after buying an additional 350,484 shares during the period.

Acadia Healthcare News Summary

Here are the key news stories impacting Acadia Healthcare this week:

• Positive Sentiment: Acadia added Daniel Cancelmi to its Board of Directors, a governance move that can be viewed positively as expanding board expertise and oversight. Article Title
• Neutral Sentiment: Reported short-interest data shows zero shares and days-to-cover of 0.0 — the release appears to contain anomalous or missing data (NaN/0) and therefore provides no clear signal about bearish positioning.
• Negative Sentiment: Zacks Research cut multiple near-term and multi-year EPS estimates and keeps a “Hold” rating. Key changes include Q2 2026 EPS cut to $0.49 (from $0.66), FY2026 to $1.48 (from $1.85), and FY2027 to $1.55 (from $1.96), plus several quarter-by-quarter reductions across 2026–2027. These downward revisions lower investor expectations and are the main reason for today’s downward pressure on the stock.

Acadia Healthcare Company Profile

Acadia Healthcare Company, Inc (NASDAQ: ACHC) is a publicly traded provider of behavioral healthcare services headquartered in Franklin, Tennessee. Founded in 2005, the company has grown through organic expansion and strategic acquisitions to establish itself as a leading specialist in mental health and addiction treatment across the United States.

Acadia operates a diversified network of inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and intensive outpatient programs.